Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Market Closed 07-10 16:00:00 EDT

35.97

-0.84

-2.28%

盘后35.91

-0.06-0.17%

19:32 EDT

High37.00	Low35.27	Vol6.24M
Open36.81	D1 Closing36.81	Amplitude4.70%
Mkt Cap25.74B	Tradable Cap20.29B	Total Shares715.70M
T/O223.40M	T/O Rate1.11%	Tradable Shares564.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":35.97,"timestamp":1783713600000,"preClose":36.81,"halted":0,"volume":6237590,"hourTrading":{"tag":"盘后","latestPrice":35.91,"preClose":35.97,"latestTime":"19:32 EDT","volume":1001755,"amount":36033107.0179,"timestamp":1783726361245,"change":-0.06,"changeRate":-0.001668,"amplitude":0.001668},"delay":0,"changeRate":-0.02281988590057059,"floatShares":564000000,"shares":715701137,"eps":-0.539999,"marketStatus":"Market Closed","change":-0.84,"latestTime":"07-10 16:00:00 EDT","open":36.81,"high":37,"low":35.27,"amount":223401681.08456,"amplitude":0.046998,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.539999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783929600000},"marketStatusCode":7,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":36.81,"preHourTrading":{"tag":"盘前","latestPrice":36.81,"preClose":36.81,"latestTime":"09:29 EDT","volume":2797,"amount":103124.70473499999,"timestamp":1783690199999,"change":0,"changeRate":0,"amplitude":0.026895},"postHourTrading":{"tag":"盘后","latestPrice":35.91,"preClose":35.97,"latestTime":"19:32 EDT","volume":1001755,"amount":36033107.0179,"timestamp":1783726361245,"change":-0.06,"changeRate":-0.001668,"amplitude":0.001668},"volumeRatio":1.164196993662382,"impliedVol":0.4045,"impliedVolPercentile":0.5936},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"2649867102","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649867102?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:02","pubTimestamp":1783371732,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $3.46 millionImmunovant CEO Eric Venker acquired 92,188 common shares on July 1, 2026 at $14.46 per share.He disposed of 86,629 shares on Jul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLj4h1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PTH","BK4139","BK4007","ROIV","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648113639","title":"Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2648113639","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648113639?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:04","pubTimestamp":1783033476,"startTime":"0","endTime":"0","summary":"Roivant director Meghan FitzGerald disposes of 10,000 common shares worth $349,000Roivant Sciences director Meghan FitzGerald exercised stock options for 10,000 common shares on June 30 at USD 8.8.Fit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL835N5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Director Meghan Fitzgerald Disposes of 10,000 Common Shares Worth $349,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648524102","title":"Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2648524102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648524102?lang=en_us&edition=fundamental","pubTime":"2026-07-02 06:34","pubTimestamp":1782945297,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Melissa B. Epperly disposes of common shares worth $610,588.76Roivant Sciences director Melissa B. Epperly sold 17,750 common shares on June 29, 2026, cutting her stake to 16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL9X1V8V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Melissa B. Epperly Disposes of Common Shares Worth $610,588.76","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648577593","title":"QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648577593","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648577593?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:00","pubTimestamp":1782864006,"startTime":"0","endTime":"0","summary":"QVT Financial reports Roivant Sciences common share disposal worth $48.57 millionQVT Financial reported selling 1,438,163 Roivant Sciences common shares from June 26 to June 30.Sales were priced betwe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL4DQ200:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"QVT Financial Reports Roivant Sciences Common Share Disposal Worth $48.57 Million","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535294","title":"Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535294","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647535294?lang=en_us&edition=fundamental","pubTime":"2026-06-30 15:17","pubTimestamp":1782803829,"startTime":"0","endTime":"0","summary":"In late June 2026, Roivant Sciences Ltd. was removed from both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index, reflecting changes in these benchmarks’ constituent lists. \nThis dual index removal highlights how shifts in passive investment flows and institutional portfolio construction can influence how a biopharmaceutical company is perceived in the market. \nWe’ll now examine how Roivant’s removal from key Russell defensive indices may affect its existing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/is-roivant-sciences-roiv-losing-its-defensive-status-or-refr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/is-roivant-sciences-roiv-losing-its-defensive-status-or-refr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CHAT","AGIX","BK4007","AIPO","BK4139","ARTY","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647300542","title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647300542","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647300542?lang=en_us&edition=fundamental","pubTime":"2026-06-30 06:23","pubTimestamp":1782771819,"startTime":"0","endTime":"0","summary":"Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $34.1 millionRoivant Sciences President and CIO Mayukh Sukhatme exercised 1 million stock options at $3.85 on June 25-26.He sold ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL2DKN99:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $34.1 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646974395","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015","url":"https://stock-news.laohu8.com/highlight/detail?id=2646974395","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646974395?lang=en_us&edition=fundamental","pubTime":"2026-06-27 07:43","pubTimestamp":1782517435,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $57,015Immunovant director Atul Pande exercised stock options for 1,500 common shares at $8.43 on June 26, 2026.Pande sold 1,500 comm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLSyS6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IMVT","BK4585","BK4588","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393286","title":"Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393286","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393286?lang=en_us&edition=fundamental","pubTime":"2026-06-27 06:14","pubTimestamp":1782512070,"startTime":"0","endTime":"0","summary":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of common shares worth $6.63 millionRoivant Sciences President and Immunovant CEO Eric Venker exercised stock options for 200,000 com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL3gJsLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4588","BK4007","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767441","title":"Immunovant director Atul Pande disposes of USD 51,030 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767441","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644767441?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:03","pubTimestamp":1781640228,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande sold 1,500 shares on June 15, 2026 at USD 34.02.He also acquired 1,500 shares the same day via option exercise at USD 8.43.Derivative holdings included 69,681 stock options following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6VlcnR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","ROIV","IMVT","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643975945","title":"Piper Sandler Sticks to Their Buy Rating for Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643975945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643975945?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607627,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00. According to TipRanks, Rah...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639260672","title":"Immunovant director Andrew J. Fromkin reports common share disposal worth $7.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2639260672","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639260672?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:05","pubTimestamp":1780085153,"startTime":"0","endTime":"0","summary":"Immunovant director Andrew J. Fromkin sold 221,951 shares on May 28, 2026 at weighted-average prices of $32.64 and $33.56.He exercised stock options for 196,601 shares the same day at exercise prices ranging from $4.99 to $14.7.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL1j1p0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMVT","BK4588","ROIV","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638517649","title":"Roivant Sciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638517649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638517649?lang=en_us&edition=fundamental","pubTime":"2026-05-26 21:07","pubTimestamp":1779800820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 26, 2026 09:07 ET (13:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638161785","title":"Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638161785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638161785?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:00","pubTimestamp":1779793250,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Crescent Biopharma (CBIO) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-crescent-biopharma-cbio-and-genmab-gmab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-crescent-biopharma-cbio-and-genmab-gmab-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LU0029874061.USD","XLV","BK4585","BK4137","XBI","LABU","GMAB","BK4588","CBIO","HCSG","ROIV","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638393735","title":"Roivant Sciences price target raised to $31.50 from $29.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2638393735","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638393735?lang=en_us&edition=fundamental","pubTime":"2026-05-25 17:00","pubTimestamp":1779699655,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $31.50 from $29.50 and keeps a Neutral rating on the shares. The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-31-50-from-29-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-31-50-from-29-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347691","title":"Roivant President, Immunovant CEO Eric Venker disposes common shares worth $7.23 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347691","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347691?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:26","pubTimestamp":1779488781,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker reported the sale of 200,000 common shares on May 22 at a weighted average price of $30.27.He also exercised stock options for 200,000 common shares on May 22 at $3.85.Venker disposed of 34,483 common shares on May 20 at $32.41.He held 1,613,063 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8bLkBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4007","ROIV","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637311253","title":"Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637311253","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637311253?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:36","pubTimestamp":1779449773,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported past fourth-quarter 2026 results showing sales of US$2.52 million versus US$7.57 million a year earlier, with net income of US$302.99 million replacing a net loss of US$206.48 million.\nThis sharp quarterly swing to profitability came despite full-year sales falling to US$8.26 million from US$29.05 million, highlighting the impact of one-off items and cost or portfolio shifts on the bottom line.\nNext, we will examine how Roivant’s unexpected quarterly profitability...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-oneoff-driven-profitability-shift-require-ac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/should-roivants-oneoff-driven-profitability-shift-require-ac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","ISBC","BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380281","title":"Roivant Sciences Price Target Maintained With a $34.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380281","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380281?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:10","pubTimestamp":1779361800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 07:10 ET (11:10 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637382584","title":"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Kindly MD (NAKA) and Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637382584","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637382584?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:20","pubTimestamp":1779358807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Incyte (INCY), Kindly MD (NAKA) and Roivant Sciences...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-incyte-incy-kindly-md-naka-and-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-incyte-incy-kindly-md-naka-and-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INCY","BK4585","XBI","BK4196","LABU","BK4550","HCSG","BK4588","BK4007","LU0128526141.USD","BK4581","BK4532","ROIV","NAKA","BK4139","BK4137","MD","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637686384","title":"Roivant Sciences Ltd : Leerink Partners Raises Target Price to $42 From $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2637686384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637686384?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:05","pubTimestamp":1779357912,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y09H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637877037","title":"Immunovant director Atul Pande disposes 6,000 shares for $192,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2637877037","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637877037?lang=en_us&edition=fundamental","pubTime":"2026-05-21 09:22","pubTimestamp":1779326554,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande reported selling 6,000 common shares at USD 32 on May 20, 2026.The sale followed the exercise of 6,000 stock options at USD 8.43 per share on the same day.Pande’s direct common share holdings fell to 116,731 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLbXDHhV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IMVT","BK4585","BK4588","ROIV"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0239},{"period":"1month","weight":0.2661},{"period":"3month","weight":0.2751},{"period":"6month","weight":0.6365},{"period":"1year","weight":2.1089},{"period":"ytd","weight":0.6576}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1111},{"period":"6month","weight":0.0877},{"period":"1year","weight":0.2063},{"period":"ytd","weight":0.1071}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.833333,"avgChangeRate":0.036544},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}